Multigene Panel Testing Identifies Women With Elevated Risk for TNBC

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer associated with more advanced disease at diagnosis and fewer effective treatment options than other forms of breast cancer. While BRCA1 and BRCA2 mutations are known to be associated with an increased risk of TNBC, little is known about other genes that may predispose […]

Read More

Resistance Mechanisms to Osimertinib in Advanced T790M-Positive NSCLC

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is currently used to treat patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC), including those with acquired resistance to prior TKI therapy through development of the T790M resistance mutation. In patients with T790M mutations, osimertinib is associated with a high response rate and […]

Read More

Modified DCF Chemotherapy Highly Effective in Advanced Anal Cancer

Although anal squamous cell carcinoma (ASCC) is a rare disease, incidence of this malignancy is gradually increasing in association with human papillomavirus (HPV) infection. While patients with early stage disease can be treated with surgery, chemotherapy, and radiation, about 35% are diagnosed at a metastatic stage or with recurrent disease after initial chemoradiotherapy. Current treatment […]

Read More

T-DM1 Active in HER2-Mutated Lung Cancer

Human epidermal growth factor receptor 2 (HER2) gene mutations have been detected in a range of cancers, including in approximately 2% of patients with lung adenocarcinoma. HER2 mutations are typically not associated with HER2 amplification and represent a distinct subgroup of HER2-activated lung cancer that may be missed by standard analyses of HER2 positivity based […]

Read More

New PD-1 Blocker For Cutaneous Squamous Cell Carcinoma

While the vast majority of patients with cutaneous squamous cell carcinoma (CSCC) are cured with surgery, approximately 5% develop advanced disease. Currently there are no systemic therapies approved for treatment of advanced CSCC, and most patients receive palliative care. Because CSCC occurs commonly in immunosuppressed patients and is associated with a high tumor mutation burden, […]

Read More

Enzalutamide: New Treatment for Nonmetastatic CRPC

Prior to this year, there were no approved treatment options for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), and the majority continued to receive androgen deprivation therapy (ADT) alone, despite limited benefit. In these patients, a rapidly rising prostate specific antigen (PSA) level is associated with a higher risk of metastasis and shorter survival. The […]

Read More

High Major Pathologic Response With Neoadjuvant Nivolumab in Resectable NSCLC

Immunotherapies targeting PD-1 and PD-L1 have become standards-of-care across all lines of therapy for patients with metastatic non-small cell lung cancer (NSCLC) who do not have targetable driver mutations. Furthermore, the PD-L1 inhibitor durvalumab was recently approved as consolidation therapy after chemoradiation in locally advanced NSCLC.  Based on the improved outcomes seen with these agents […]

Read More

Immunoscore Reliable to Estimate Risk of Recurrence in Early CRC

Currently, the risk of recurrence after surgery for patients with colorectal cancer (CRC) is estimated based on histopathological criteria of tumor invasion according to the American Joint Committee on Cancer (AJCC) and TNM classification system and on features of tumor cell differentiation. In recent years, the role of the immune system in cancer patient outcomes […]

Read More

Total Neoadjuvant Therapy Improves R0 Resection Rate in Borderline Resectable Pancreatic Adenocarcinoma

For patients with localized pancreatic adenocarcinoma with some degree of vascular involvement (as defined by National Comprehensive Cancer Network [NCCN]), termed borderline resectable, management has been heterogeneous and includes neoadjuvant chemoradiation, surgery, and most recently, neoadjuvant therapy. Retrospective data indicate that neoadjuvant chemotherapy can improve rates of R0 resection in patients with borderline resectable disease. […]

Read More

CLL,venetoclax/Rituximab

Venetoclax Induces Durable Responses in R/R CLL With 17p Deletion

In patients with chronic lymphocytic leukemia (CLL), deletion of chromosome 17p [del(17p)] or mutation in TP53 is associated with poor prognosis and resistance to many standard therapies. The recent emergence of targeted therapies has expanded available treatment options for these patients. The B-cell lymphoma 2 inhibitor venetoclax was approved for the treatment of CLL with […]

Read More